According to Zen Score, the 3 best medical stocks to buy right now are:
1. Orasure Technologies (NASDAQ:OSUR)
Orasure Technologies (NASDAQ:OSUR) is the top medical stock with a Zen Score of 59, which is 28 points higher than the medical industry average of 31. It passed 18 out of 33 due diligence checks and has strong fundamentals. Orasure Technologies has seen its stock lose -19.88% over the past year, underperforming other medical stocks by -8 percentage points.
Orasure Technologies has an average 1 year
price target of $6.83, an upside of 28.44% from Orasure Technologies's current stock price of $5.32.
Orasure Technologies stock has a consensus Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Orasure Technologies, 33.33% have issued a Strong Buy rating, 0% have issued a Buy, 66.67% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.
2. Staar Surgical Co (NASDAQ:STAA)
Staar Surgical Co (NASDAQ:STAA) is the second best medical stock with a Zen Score of 53, which is 22 points higher than the medical industry average of 31. It passed 18 out of 33 due diligence checks and has strong fundamentals. Staar Surgical Co has seen its stock lose -30.53% over the past year, underperforming other medical stocks by -19 percentage points.
Staar Surgical Co has an average 1 year
price target of $44.33, a downside of -5.59% from Staar Surgical Co's current stock price of $46.96.
Staar Surgical Co stock has a consensus Buy recommendation according to Wall Street analysts. Of the 6 analysts covering Staar Surgical Co, 33.33% have issued a Strong Buy rating, 16.67% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.
3. Utah Medical Products (NASDAQ:UTMD)
Utah Medical Products (NASDAQ:UTMD) is the third best medical stock with a Zen Score of 52, which is 21 points higher than the medical industry average of 31. It passed 18 out of 38 due diligence checks and has strong fundamentals. Utah Medical Products has seen its stock lose -30.5% over the past year, underperforming other medical stocks by -19 percentage points.